1223498-69-8 Usage
Description
BAY 1000394, also known as Roniciclib, is a type I pan-CDK inhibitor that has been developed for its potential use in the treatment of various types of cancer. It works by inhibiting the activity of cyclin-dependent kinases (CDKs), which play a crucial role in regulating cell cycle progression and are often dysregulated in cancer cells. This inhibition can lead to cell cycle arrest and apoptosis, ultimately resulting in the suppression of tumor growth.
Uses
Used in Anticancer Applications:
BAY 1000394 is used as an anticancer agent for its ability to inhibit the activity of cyclin-dependent kinases (CDKs) in cancer cells. This inhibition can lead to cell cycle arrest and apoptosis, which can help in the suppression of tumor growth and progression. It is particularly effective in xenograft cancer models, where it has shown promising results in targeting various types of cancer.
Used in Pharmaceutical Industry:
BAY 1000394 is used as a potential therapeutic agent in the pharmaceutical industry for its ability to target and inhibit the activity of cyclin-dependent kinases (CDKs) in cancer cells. Its development and application in this industry can contribute to the advancement of cancer treatment options and improve patient outcomes.
Used in Research and Development:
BAY 1000394 is used as a research tool in the field of oncology to better understand the role of CDKs in cancer cell proliferation and survival. Its application in research and development can help in the discovery of novel therapeutic strategies and the development of more effective cancer treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 1223498-69-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,3,4,9 and 8 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1223498-69:
(9*1)+(8*2)+(7*2)+(6*3)+(5*4)+(4*9)+(3*8)+(2*6)+(1*9)=158
158 % 10 = 8
So 1223498-69-8 is a valid CAS Registry Number.
1223498-69-8Relevant articles and documents
The lab oddity prevails: Discovery of Pan-CDK inhibitor (R)-S-Cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY1000394) for the treatment of cancer
Luecking, Ulrich,Jautelat, Rolf,Krueger, Martin,Brumby, Thomas,Lienau, Philip,Schaefer, Martina,Briem, Hans,Schulze, Julia,Hillisch, Alexander,Reichel, Andreas,Wengner, Antje Margret,Siemeister, Gerhard
, p. 1067 - 1085 (2013/07/26)
Lead optimization of a high-throughput screening hit led to the rapid identification of aminopyrimidine ZK304709, a multitargeted CDK and VEGF-R inhibitor that displayed a promising preclinical profile. Nevertheless, ZK304709 failed in phaseI studies due
SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE
-
Page/Page column 8-9, (2011/12/13)
The invention relates to sulfoximine-substituted anilino-pyrimidine derivatives of formula (I). methods of production thereof, and use thereof as medication for the treatment of various diseases.
